These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
824 related articles for article (PubMed ID: 34138694)
21. Impact of COVID-19 on vaccination programs: adverse or positive? Ali I Hum Vaccin Immunother; 2020 Nov; 16(11):2594-2600. PubMed ID: 32961081 [TBL] [Abstract][Full Text] [Related]
22. The potential effects of deploying SARS-Cov-2 vaccines on cold storage capacity and immunization workload in countries of the WHO African Region. Ortiz JR; Robertson J; Hsu JS; Yu SL; Driscoll AJ; Williams SR; Chen WH; Fitzpatrick MC; Sow S; Biellik RJ; Neuzil KM Vaccine; 2021 Apr; 39(15):2165-2176. PubMed ID: 33744049 [TBL] [Abstract][Full Text] [Related]
23. Sub-Saharan Africa Tackles COVID-19: Challenges and Opportunities. Mezue K; Edwards P; Nsofor I; Goha A; Anya I; Madu K; Baugh D; Nunura F; Gaulton G; Madu E Ethn Dis; 2020; 30(4):693-694. PubMed ID: 32989369 [TBL] [Abstract][Full Text] [Related]
24. Acceptance of COVID-19 vaccines in sub-Saharan Africa: evidence from six national phone surveys. Kanyanda S; Markhof Y; Wollburg P; Zezza A BMJ Open; 2021 Dec; 11(12):e055159. PubMed ID: 34911723 [TBL] [Abstract][Full Text] [Related]
25. High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa. Tso FY; Lidenge SJ; Peña PB; Clegg AA; Ngowi JR; Mwaiselage J; Ngalamika O; Julius P; West JT; Wood C Int J Infect Dis; 2021 Jan; 102():577-583. PubMed ID: 33176202 [TBL] [Abstract][Full Text] [Related]
26. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336 [TBL] [Abstract][Full Text] [Related]
27. [Considerations on vaccines and immunization against COVID-19 for epidemic control in China]. Zhang Q; Wang FZ; Ma C; An ZJ; Yin ZD Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Dec; 55(12):1371-1376. PubMed ID: 34963231 [TBL] [Abstract][Full Text] [Related]
28. Low coverage of COVID-19 vaccines in Africa: current evidence and the way forward. Lawal L; Aminu Bello M; Murwira T; Avoka C; Yusuf Ma'aruf S; Harrison Omonhinmin I; Maluleke P; Tsagkaris C; Onyeaka H Hum Vaccin Immunother; 2022 Dec; 18(1):2034457. PubMed ID: 35240908 [TBL] [Abstract][Full Text] [Related]
29. [Do we need a pediatric COVID-19 vaccine?]. Eberhardt CS; Siegrist CA Rev Med Suisse; 2021 Feb; 17(726):353-357. PubMed ID: 33599412 [TBL] [Abstract][Full Text] [Related]
30. COVID-19 outbreak: a potential threat to routine vaccination programme activities in Nigeria. Ogundele OA; Omotoso AA; Fagbemi AT Hum Vaccin Immunother; 2021 Mar; 17(3):661-663. PubMed ID: 32991237 [TBL] [Abstract][Full Text] [Related]
31. Prospects of COVID-19 Vaccination in Romania: Challenges and Potential Solutions. Dascalu S; Geambasu O; Covaciu O; Chereches RM; Diaconu G; Dumitra GG; Gheorghita V; Popovici ED Front Public Health; 2021; 9():644538. PubMed ID: 33643998 [TBL] [Abstract][Full Text] [Related]
32. Equitable and Feasible Distribution of SARS-CoV-2 Vaccines for All in Africa. Rogers AB; Barrie MB; Fallah MP; Kelly JD Am J Trop Med Hyg; 2021 Jun; 105(2):278-280. PubMed ID: 34181573 [TBL] [Abstract][Full Text] [Related]
33. Silent Consequences of COVID-19: Why It's Critical to Recover Routine Vaccination Rates Through Equitable Vaccine Policies and Practices. Skolnik A; Bhatti A; Larson A; Mitrovich R Ann Fam Med; 2021; 19(6):527-531. PubMed ID: 34376387 [TBL] [Abstract][Full Text] [Related]
34. A call for strengthened evidence on targeted, non-pharmaceutical interventions against COVID-19 for the protection of vulnerable individuals in sub-Saharan Africa. Colebunders R; Siewe Fodjo JN; Vanham G; Van den Bergh R Int J Infect Dis; 2020 Oct; 99():482-484. PubMed ID: 32861825 [TBL] [Abstract][Full Text] [Related]
35. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Africa: Current Considerations and Future Projections. Idoko OT; Usuf E; Okomo U; Wonodi C; Jambo K; Kampmann B; Madhi S; Adetifa I Clin Infect Dis; 2022 Aug; 75(Suppl 1):S136-S140. PubMed ID: 35749696 [TBL] [Abstract][Full Text] [Related]
36. The global COVID-19 vaccine surplus: tackling expiring stockpiles. Quan NK; Anh NLM; Taylor-Robinson AW Infect Dis Poverty; 2023 Mar; 12(1):21. PubMed ID: 36941709 [TBL] [Abstract][Full Text] [Related]
37. Leveraging HIV Program and Civil Society to Accelerate COVID-19 Vaccine Uptake, Zambia. Bobo P; Hines JZ; Chilengi R; Auld AF; Agolory SG; Silumesii A; Nkengasong J Emerg Infect Dis; 2022 Dec; 28(13):S244-S246. PubMed ID: 36502463 [TBL] [Abstract][Full Text] [Related]
38. Lessons from the team care playbook: Recommendations for COVID-19 vaccination dissemination and uptake. Polaha J; Johnson L; Quinn M; Sunderji N Fam Syst Health; 2020 Dec; 38(4):341-345. PubMed ID: 33332139 [TBL] [Abstract][Full Text] [Related]
39. COVID-19 mass vaccination campaign for healthcare workers in a low-resource setting: A clinician-driven initiative. Reddy DL; Dangor Z; Lala N; Johnstone J; Maswabi L; Tsitsi JML S Afr Med J; 2021 May; 111(7):610-614. PubMed ID: 34382541 [TBL] [Abstract][Full Text] [Related]
40. Disparities in First Dose COVID-19 Vaccination Coverage among Children 5-11 Years of Age, United States. Murthy NC; Zell E; Fast HE; Murthy BP; Meng L; Saelee R; Vogt T; Chatham-Stephens K; Ottis C; Shaw L; Gibbs-Scharf L; Harris L; Chorba T Emerg Infect Dis; 2022 May; 28(5):986-989. PubMed ID: 35226801 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]